Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block offers hope for migraine sufferers Who've tried everything

NCT ID NCT06891118

Symptom relief Sponsor: Ankara City Hospital Bilkent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 4 times

Summary

This study tested a nerve block called a stellate ganglion block for people with chronic migraine that didn't get better with other treatments. 42 patients received the injection under ultrasound guidance. Researchers tracked changes in monthly headache days and pain scores over 6 months to see if the procedure helped.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stellate ganglion block (nerve block injection)
What this could lead to
If effective, this nerve block could offer a new option for people with chronic migraine who haven't found relief from standard treatments.
What could go wrong
This is a small, single-center study with no control group, so results may not apply widely. The procedure carries risks like bleeding, infection, or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults aged 18-65 years. * Diagnosis of chronic migraine according to ICHD-3 criteria. * Insufficient clinical response to prior preventive migraine treatment. * Prior interventional headache treatment performed at least 3 months before enrollment, with insufficient clinical benefit. * Willingness and ability to participate in the study, comply with follow-up, and undergo the planned interventional treatment. Exclusion Criteria * History of a primary headache disorder other than migraine. * Migraine-related interventional treatment, botulinum toxin A treatment, or nonpharmacological headache treatment (e.g., acupuncture, ozone therapy, or cognitive behavioral therapy) within the previous 3 months. * Infection at the planned injection site. * Pregnancy or suspected pregnancy. * Known allergy to local anesthetic agents. * History of malignancy or cranial/cervical surgery. * Bleeding or coagulation disorder, or current oral anticoagulant therapy. * Comorbid conditions that could contribute to headache, such as uncontrolled hypertension or intracranial lesions. * Conditions that could impair adherence to the treatment or follow-up protocol, such as significant psychiatric disease or dementia. * Unwillingness to undergo the planned interventional treatment or to continue the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic migraine headache are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

headache disorder migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic migraine headache Headache, migraine

Contacts and locations

Locations

  • Health Sciences University, Ankara Bilkent City Hospital

    Ankara, Cankaya, 06800, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.